# Tanios Bekaii-Saab

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 212 papers | 8,765 citations | 46 h-index | 89 g-index |
| 225 ext. papers | 10,925 ext. citations | 6 avg, IF | 5.86 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 212 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet, The*, **2020**, 395, 1907-1918 | 40 | 880 |
| 211 | Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet, The*, **2016**, 387, 545-557 | 40 | 630 |
| 210 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. *Journal of Clinical Oncology*, **2018**, 36, 276-282 | 2.2 | 357 |
| 209 | Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. *Cancer Research*, **2013**, 73, 3007-18 | 10.1 | 267 |
| 208 | Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. *JAMA Surgery*, **2016**, 151, e161137 | 5.4 | 263 |
| 207 | IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. *Gut*, **2018**, 67, 320-332 | 19.2 | 255 |
| 206 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. *Journal of Clinical Oncology*, **2011**, 29, 2357-63 | 2.2 | 233 |
| 205 | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncology, The*, **2017**, 18, 446-453 | 21.7 | 223 |
| 204 | Biliary cancer: Utility of next-generation sequencing for clinical management. *Cancer*, **2016**, 122, 3838-3847 | 6.4 | 185 |
| 203 | Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. *Annals of Surgical Oncology*, **2015**, 22, 1153-9 | 3.1 | 184 |
| 202 | Pain, depression, and fatigue: loneliness as a longitudinal risk factor. *Health Psychology*, **2014**, 33, 948-57 | 5 | 173 |
| 201 | Colon cancer, version 3.2014. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1028-59 | 7.3 | 171 |
| 200 | Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *Journal of Clinical Oncology*, **2019**, 37, 1015-1027 | 2.2 | 157 |
| 199 | Rectal Cancer, Version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 719-28; quiz 728 | 7.3 | 154 |
| 198 | A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. *Cancer*, **2013**, 119, 2692-700 | 6.4 | 138 |
| 197 | Rectal cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 1528-64 | 7.3 | 127 |
| 196 | Gastric cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 378-409 | 7.3 | 119 |

| | | | |
|---|---|---|---|
| 195 | Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 141-52; quiz 152 | 7.3 | 118 |
| 194 | Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. *Journal of the National Cancer Institute*, **2019**, 111, 782-794 | 9.7 | 113 |
| 193 | Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1269-79 | 7.4 | 108 |
| 192 | STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. *Biochemical and Biophysical Research Communications*, **2011**, 416, 246-51 | 3.4 | 94 |
| 191 | UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 656-65 | 4.7 | 94 |
| 190 | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. *Clinical Cancer Research*, **2009**, 15, 5895-901 | 12.9 | 91 |
| 189 | Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. *Cancer Immunology, Immunotherapy*, **2015**, 64, 149-59 | 7.4 | 83 |
| 188 | Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. *Cancer*, **2013**, 119, 285-92 | 6.4 | 80 |
| 187 | A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2016**, 22, 61-8 | 12.9 | 79 |
| 186 | Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 519-28 | 7.3 | 77 |
| 185 | HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. *Oncology*, **2012**, 82, 175-9 | 3.6 | 77 |
| 184 | Identifying and targeting cancer stem cells in the treatment of gastric cancer. *Cancer*, **2017**, 123, 1303-1312 | 6.4 | 70 |
| 183 | Prostate cancer incidence in males with Lynch syndrome. *Genetics in Medicine*, **2014**, 16, 553-7 | 8.1 | 70 |
| 182 | Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. *Oncologist*, **2015**, 20, 1132-9 | 5.7 | 69 |
| 181 | Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. *Cancer*, **2012**, 118, 5497-506 | 6.4 | 68 |
| 180 | Appendiceal Mucinous Neoplasms: Diagnosis and Management. *Oncologist*, **2017**, 22, 1107-1116 | 5.7 | 66 |
| 179 | Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. *Scientific Reports*, **2015**, 5, 10867 | 4.9 | 64 |
| 178 | Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. *Cancer Research*, **2017**, 77, 2647-2660 | 10.1 | 60 |

| | | | |
|---|---|---|---|
| 177 | Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. *Journal of the National Cancer Institute*, **2015**, 107, djv274 | 9.7 | 59 |
| 176 | Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. *Nature Communications*, **2017**, 8, 14755 | 17.4 | 56 |
| 175 | A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). *Oncologist*, **2010**, 15, 1310-9 | 5.7 | 56 |
| 174 | Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 449-54 | 7.3 | 56 |
| 173 | Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. *Clinical Cancer Research*, **2016**, 22, 2565-74 | 12.9 | 52 |
| 172 | Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. *Anti-Cancer Drugs*, **2009**, 20, 444-9 | 2.4 | 50 |
| 171 | Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. *Scientific Reports*, **2015**, 5, 12122 | 4.9 | 49 |
| 170 | Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. *JAMA Oncology*, **2020**, 6, e204930 | 13.4 | 49 |
| 169 | Antiangiogenic Therapy in Colorectal Cancer. *Cancer Journal (Sudbury, Mass.)*, **2018**, 24, 165-170 | 2.2 | 49 |
| 168 | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1499-506 | 3.5 | 47 |
| 167 | Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncology*, **2021**, | 13.4 | 47 |
| 166 | Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. *Journal of Hematology and Oncology*, **2008**, 1, 18 | 22.4 | 45 |
| 165 | A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. *Oncologist*, **2018**, 23, 25-34 | 5.7 | 44 |
| 164 | Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. *Annals of Surgery*, **2014**, 259, 102-8 | 7.8 | 42 |
| 163 | A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. *BMC Cancer*, **2006**, 6, 278 | 4.8 | 42 |
| 162 | Ampullary cancer: an overview. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, 112-5 | 7.1 | 41 |
| 161 | Colon cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9, 1238-90 | 7.3 | 39 |
| 160 | Clinical Trials and Progress in Metastatic Colon Cancer. *Surgical Oncology Clinics of North America*, **2018**, 27, 349-365 | 2.7 | 38 |

| | | | |
|---|---|---|---|
| 159 | Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. *Pancreas*, **2017**, 46, 1152-1157 | 2.6 | 38 |
| 158 | Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. *Cancer Immunology, Immunotherapy*, **2015**, 64, 727-36 | 7.4 | 37 |
| 157 | Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. *Investigational New Drugs*, **2014**, 32, 113-22 | 4.3 | 37 |
| 156 | Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. *Journal of the National Cancer Institute*, **2015**, 107, 362 | 9.7 | 37 |
| 155 | Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. *Annals of Surgical Oncology*, **2016**, 23, 2281-6 | 3.1 | 37 |
| 154 | Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. *Journal of the American College of Surgeons*, **2013**, 217, 347-57.e1 | 4.4 | 35 |
| 153 | Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. *Cancer*, **2016**, 122, 3657-3666 | 6.4 | 35 |
| 152 | Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. *Carcinogenesis*, **2014**, 35, 2203-13 | 4.6 | 34 |
| 151 | Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. *Journal of Immunology*, **2013**, 191, 217-27 | 5.3 | 34 |
| 150 | Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. *Cancer Treatment Reviews*, **2017**, 60, 109-119 | 14.4 | 34 |
| 149 | A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. *Therapeutic Advances in Medical Oncology*, **2017**, 9, 75-82 | 5.4 | 34 |
| 148 | Cholangiocarcinoma With Genetic Aberrations: A Unique Clinical Phenotype.. *JCO Precision Oncology*, **2018**, 2, 1-12 | 3.6 | 33 |
| 147 | IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. *Clinical Cancer Research*, **2017**, 23, 489-502 | 12.9 | 32 |
| 146 | Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. *Clinical Colorectal Cancer*, **2019**, 18, e117-e129 | 3.8 | 32 |
| 145 | Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2017**, 40, 569-573 | 2.7 | 29 |
| 144 | Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. *JAMA Surgery*, **2014**, 149, 18-25 | 5.4 | 29 |
| 143 | Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. *Lasers in Surgery and Medicine*, **2006**, 38, 881-9 | 3.6 | 29 |
| 142 | Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2019**, 25, 2403-2413 | 12.9 | 29 |

| | | | |
|---|---|---|---|
| 141 | The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. *JAMA Oncology*, **2020**, 6, e194489 | 13.4 | 28 |
| 140 | Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. *Oncogene*, **2018**, 37, 3440-3455 | 9.2 | 27 |
| 139 | Biliary cancer: intrahepatic cholangiocarcinoma extrahepatic cholangiocarcinoma gallbladder cancers: classification and therapeutic implications. *Journal of Gastrointestinal Oncology*, **2017**, 8, 293-301 | 2.8 | 26 |
| 138 | Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1123-30 | 7.3 | 25 |
| 137 | Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. *Cancer*, **2017**, 123, 4680-4686 | 6.4 | 25 |
| 136 | Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. *Genetics in Medicine*, **2016**, 18, 863-8 | 8.1 | 24 |
| 135 | Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. *Critical Reviews in Oncology/Hematology*, **2014**, 91, 9-34 | 7 | 24 |
| 134 | Esophageal Cancer Clinical Practice Guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 328-47 | 7.3 | 24 |
| 133 | Gastric Cancer Clinical Practice Guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 350-66 | 7.3 | 24 |
| 132 | A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. *Investigational New Drugs*, **2012**, 30, 629-38 | 4.3 | 23 |
| 131 | Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. *Frontiers in Oncology*, **2016**, 6, 148 | 5.3 | 23 |
| 130 | A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. *Investigational New Drugs*, **2013**, 31, 685-95 | 4.3 | 22 |
| 129 | Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. *Cancer*, **2014**, 120, 1780-6 | 6.4 | 22 |
| 128 | Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. *Clinical Colorectal Cancer*, **2012**, 11, 195-9 | 3.8 | 22 |
| 127 | Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2019**, 25, 3495-3507 | 12.9 | 21 |
| 126 | Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. *Molecular Cancer Therapeutics*, **2017**, 16, 344-356 | 6.1 | 20 |
| 125 | Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. *Molecular Cancer Research*, **2017**, 15, 26-34 | 6.6 | 20 |
| 124 | Selumetinib for the treatment of cancer. *Expert Opinion on Investigational Drugs*, **2015**, 24, 111-123 | 5.9 | 20 |

| | | | |
|---|---|---|---|
| 123 | Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. *Cancer*, **2012**, 118, 6243-52 | 6.4 | 20 |
| 122 | Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. *Cancer Research and Treatment*, **2016**, 48, 596-604 | 5.2 | 20 |
| 121 | Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. *Biomedicines*, **2019**, 7, | 4.8 | 19 |
| 120 | Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2010**, 66, 1019-29 | 3.5 | 18 |
| 119 | Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. *Medical Oncology*, **2016**, 33, 48 | 3.7 | 18 |
| 118 | Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. *Medical Oncology*, **2012**, 29, 3101-7 | 3.7 | 17 |
| 117 | Integrating anti-EGFR therapies in metastatic colorectal cancer. *Journal of Gastrointestinal Oncology*, **2013**, 4, 285-98 | 2.8 | 17 |
| 116 | CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. *Future Oncology*, **2019**, 15, 1295-1302 | 3.6 | 17 |
| 115 | Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.. *JCO Precision Oncology*, **2019**, 3, 1-9 | 3.6 | 17 |
| 114 | Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. *Investigational New Drugs*, **2011**, 29, 347-51 | 4.3 | 16 |
| 113 | A clinical trial protocol paper discussing the BRIGHTER study. *Future Oncology*, **2018**, 14, 901-906 | 3.6 | 15 |
| 112 | A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, e475-81 | 4 | 15 |
| 111 | Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 298-307; quiz 307 | 7.3 | 15 |
| 110 | Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. *Expert Opinion on Investigational Drugs*, **2021**, 30, 309-316 | 5.9 | 15 |
| 109 | Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. *Cancers*, **2021**, 13, | 6.6 | 15 |
| 108 | Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. *Journal of the National Cancer Institute*, **2016**, 108, | 9.7 | 14 |
| 107 | Adjuvant therapy for pancreas cancer in an era of value based cancer care. *Cancer Treatment Reviews*, **2016**, 42, 10-7 | 14.4 | 14 |
| 106 | Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. *Neoplasia*, **2016**, 18, 765-774 | 6.4 | 14 |

| | | | |
|---|---|---|---|
| 105 | Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. *Cancers*, **2019**, 11, | 6.6 | 13 |
| 104 | Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 235-43 | 7.3 | 13 |
| 103 | Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). *Vaccines*, **2015**, 3, 519-43 | 5.3 | 13 |
| 102 | Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. *Journal of Thoracic Oncology*, **2010**, 5, 713-8 | 8.9 | 13 |
| 101 | Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2016**, 39, 614-618 | 2.7 | 13 |
| 100 | Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. *Cancers*, **2018**, 10, | 6.6 | 12 |
| 99 | Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. *BMC Cancer*, **2017**, 17, 262 | 4.8 | 12 |
| 98 | Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. *Clinical Colorectal Cancer*, **2016**, | 3.8 | 12 |
| 97 | Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. *European Journal of Cancer*, **2020**, 132, 112-121 | 7.5 | 12 |
| 96 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. *Pancreatology*, **2020**, 20, 101-109 | 3.8 | 12 |
| 95 | Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 1528-1534 | 7.3 | 12 |
| 94 | Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2017**, 40, 561-568 | 2.7 | 11 |
| 93 | Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. *EMBO Molecular Medicine*, **2020**, 12, e9910 | 12 | 11 |
| 92 | Clinical update on K-Ras targeted therapy in gastrointestinal cancers. *Critical Reviews in Oncology/Hematology*, **2018**, 130, 78-91 | 7 | 11 |
| 91 | What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. *Surgery*, **2013**, 154, 1100-9 | 3.6 | 11 |
| 90 | A RAND/UCLA appropriateness study of the management of familial gastric cancer. *Annals of Surgical Oncology*, **2013**, 20, 533-41 | 3.1 | 11 |
| 89 | A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2010**, 66, 151-8 | 3.5 | 11 |
| 88 | Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. *Oncotarget*, **2015**, 6, 44509-22 | 3.3 | 11 |

| | | | |
|---|---|---|---|
| 87 | Hepatobiliary cancers. Clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 728-50 | 7.3 | 11 |
| 86 | Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. *Pancreatology*, **2019**, 19, 80-87 | 3.8 | 11 |
| 85 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. *Pancreas*, **2020**, 49, 193-200 | 2.6 | 10 |
| 84 | Late relapse of ovarian dysgerminoma: case report and literature review. *Gynecologic Oncology*, **1999**, 72, 111-2 | 4.9 | 10 |
| 83 | Genomic diversity of colorectal cancer: Changing landscape and emerging targets. *World Journal of Gastroenterology*, **2016**, 22, 5668-77 | 5.6 | 10 |
| 82 | Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. *Advances in Radiation Oncology*, **2018**, 3, 34-41 | 3.3 | 9 |
| 81 | Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. *Journal of Hepatology*, **2020**, 73, 1109-1117 | 13.4 | 9 |
| 80 | The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2017**, 40, 531-534 | 2.7 | 8 |
| 79 | The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. *Biomedicines*, **2017**, 5, | 4.8 | 8 |
| 78 | Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. *Journal of Gastrointestinal Surgery*, **2014**, 18, 2186-91 | 3.3 | 8 |
| 77 | Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. *Pancreas*, **2014**, 43, 343-9 | 2.6 | 8 |
| 76 | Emerging treatments in recurrent and metastatic colorectal cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11 Suppl 4, S18-27 | 7.3 | 8 |
| 75 | Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. *Clinical and Translational Gastroenterology*, **2019**, 10, e00098 | 4.2 | 8 |
| 74 | A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. *Investigational New Drugs*, **2021**, 1 | 4.3 | 8 |
| 73 | Therapeutic options for intrahepatic cholangiocarcinoma. *Hepatobiliary Surgery and Nutrition*, **2017**, 6, 91-100 | 2.1 | 7 |
| 72 | Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. *Clinical Colorectal Cancer*, **2016**, 15, e61-3 | 3.8 | 7 |
| 71 | A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. *Cancer Chemotherapy and Pharmacology*, **2011**, 67, 511-7 | 3.5 | 7 |
| 70 | An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 895-900 | 7.3 | 7 |

| | | | |
|---|---|---|---|
| 69 | Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. *OncoImmunology*, **2020**, 9, 1818437 | 7.2 | 7 |
| 68 | ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. *Clinical Cancer Research*, **2021**, 27, 3641-3648 | 12.9 | 7 |
| 67 | Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. *Gastrointestinal Cancer: Targets and Therapy*, **2016**, 6, 21-30 | | 7 |
| 66 | A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. *Oncologist*, **2019**, 24, 1174-1179 | 5.7 | 7 |
| 65 | Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. *International Journal of Cancer*, **2018**, 142, 1671-1675 | 7.5 | 7 |
| 64 | Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. *Chinese Clinical Oncology*, **2020**, 9, 6 | 2.3 | 6 |
| 63 | Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. *Oncotarget*, **2015**, 6, 22206-13 | 3.3 | 6 |
| 62 | Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. *Oncotarget*, **2016**, 7, 5306-12 | 3.3 | 6 |
| 61 | Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. *Scientific Reports*, **2020**, 10, 22087 | 4.9 | 6 |
| 60 | Practical considerations in the use of regorafenib in metastatic colorectal cancer. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920956862 | 5.4 | 6 |
| 59 | Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. *Pancreatology*, **2020**, 20, 1115-1122 | 3.8 | 6 |
| 58 | Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. *Oncologist*, **2021**, 26, 668-675 | 5.7 | 6 |
| 57 | Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. *Seminars in Liver Disease*, **2021**, 41, 136-141 | 7.3 | 6 |
| 56 | Improvements in Clinical Outcomes for -Mutant Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2020**, 26, 4435-4441 | 12.9 | 6 |
| 55 | A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. *Oncologist*, **2020**, 25, 203-207 | 5.7 | 5 |
| 54 | Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 140-146 | 2.7 | 5 |
| 53 | Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. *Small GTPases*, **2018**, 9, 452-456 | 2.7 | 5 |
| 52 | Outcomes of definitive chemoradiation in patients with esophageal cancer. *Ecological Management and Restoration*, **2017**, 30, 1-7 | 3 | 5 |

| | | | |
|---|---|---|---|
| 51 | O-0002 A Phase 2 Adjuvant Trial of GI-4000 Plus Gemcitabine vs. Gemcitabine Alone in Ras+ Patients with Resected Pancreas Cancer: R1 Subgroup Analysis. *Annals of Oncology*, **2012**, 23, iv5 | 10.3 | 5 |
| 50 | A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. *Onkologie*, **2013**, 36, 657-60 | | 5 |
| 49 | Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.. *JCO Precision Oncology*, **2022**, 6, e2100156 | 3.6 | 5 |
| 48 | Application of next-generation sequencing in gastrointestinal and liver tumors. *Cancer Letters*, **2016**, 374, 187-91 | 9.9 | 4 |
| 47 | The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. *Annals of Surgical Oncology*, **2014**, 21, 862-867 | 3.1 | 4 |
| 46 | Moving forward with expanding to an "all-RAS mutational analysis" in metastatic colorectal cancer: beyond KRAS mutations. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 299-300 | 7.3 | 4 |
| 45 | A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer*, **2013**, 79, 27-32 | 5.9 | 4 |
| 44 | FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?. *Oncologist*, **2013**, 18, 487-9 | 5.7 | 4 |
| 43 | Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. *Cancer Chemotherapy and Pharmacology*, **2010**, 65, 319-24 | 3.5 | 4 |
| 42 | First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. *European Journal of Cancer*, **2021**, 151, 14-24 | 7.5 | 4 |
| 41 | Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. *Clinical Cancer Research*, **2020**, 26, 3117-3125 | 12.9 | 4 |
| 40 | Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.. *JAMA Network Open*, **2022**, 5, e2149040 | 10.4 | 4 |
| 39 | Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. *JAMA Network Open*, **2022**, 5, e224304 | 10.4 | 4 |
| 38 | Signaling pathways as therapeutic targets in biliary tract cancer. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 485-498 | 6.4 | 3 |
| 37 | KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. *Clinical Colorectal Cancer*, **2009**, 8, 135-40 | 3.8 | 3 |
| 36 | MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. *OncoTargets and Therapy*, **2016**, 9, 5931-5941 | 4.4 | 3 |
| 35 | A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. *Journal of Gastrointestinal Oncology*, **2018**, 9, 1063-1073 | 2.8 | 3 |
| 34 | Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2015**, 15, 133-43 | 2.2 | 2 |

| | | | |
|---|---|---|---|
| 33 | Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. *Cancer Chemotherapy and Pharmacology*, **2015**, 76, 1005-12 | 3.5 | 2 |
| 32 | Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. *Photomedicine and Laser Surgery*, **2012**, 30, 668-71 | | 2 |
| 31 | A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. *Journal of Gastrointestinal Oncology*, **2015**, 6, 336-40 | 2.8 | 2 |
| 30 | CA 19-9 as a Serum Biomarker in Cancer. *Biomarkers in Disease*, **2015**, 179-201 | | 2 |
| 29 | A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. *Cancer Immunology, Immunotherapy*, **2021**, 70, 3337-3348 | 7.4 | 2 |
| 28 | Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. *Targeted Oncology*, **2016**, 11, 807-814 | 5 | 2 |
| 27 | Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. *Pancreatology*, **2021**, 21, 192-199 | 3.8 | 2 |
| 26 | Maintenance therapy for colorectal cancer: which regimen and which patients?. *Drugs*, **2015**, 75, 1833-42 | 12.1 | 1 |
| 25 | Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. *Journal of Oncology Practice*, **2017**, 13, e62-e67 | 3.1 | 1 |
| 24 | Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. *Medical Oncology*, **2016**, 33, 4 | 3.7 | 1 |
| 23 | Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. *Oncology*, **2012**, 83, 135-40 | 3.6 | 1 |
| 22 | Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds. *Clinical and Applied Thrombosis/Hemostasis*, **2012**, 18, 104-6 | 3.3 | 1 |
| 21 | Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, | 4.5 | 1 |
| 20 | Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. *JAMA Network Open*, **2021**, 4, e2134458 | 10.4 | 1 |
| 19 | FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. *Digestive Diseases and Sciences*, **2021**, 1 | 4 | 1 |
| 18 | Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. *JAMA Network Open*, **2022**, 5, e2142046 | 10.4 | 1 |
| 17 | Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42 | | 1 |
| 16 | Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. *British Journal of Cancer*, **2020**, 123, 1377-1386 | 8.7 | 1 |

# List of Publications

| | | | |
|---|---|---|---|
| 15 | The Role of Maintenance Therapy in Metastatic Colorectal Cancer-Reply. *JAMA Oncology*, **2020**, 6, 937-938 | 13.4 | 1 |
| 14 | Frontline therapy for advanced hepatocellular carcinoma: an update.. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 17562848221086126 | 4.7 | 1 |
| 13 | Watch and Wait in Rectal Cancer: Who In and Who Out?. *Journal of Oncology Practice*, **2019**, 15, 133-134 | 3.1 | 0 |
| 12 | Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. *Oncologist*, **2020**, 25, e1246-e1248 | 5.7 | 0 |
| 11 | Response to Drs Von Hoff and Renschler. *Therapeutic Advances in Medical Oncology*, **2017**, 9, 445-446 | 5.4 | |
| 10 | Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. *Current Colorectal Cancer Reports*, **2016**, 12, 260-265 | 1 | |
| 9 | CA 19-9 as a Serum Biomarker in Cancer **2014**, 1-19 | | |
| 8 | Adjuvant Therapy Following Curative Resection of Metastases. *Current Colorectal Cancer Reports*, **2012**, 8, 217-224 | 1 | |
| 7 | RASmutations: impact on treatment outcome. *Colorectal Cancer*, **2013**, 2, 525-534 | 0.8 | |
| 6 | A phase I study of topotecan and gemcitabine in advanced solid tumors. *Investigational New Drugs*, **2011**, 29, 1390-4 | 4.3 | |
| 5 | A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. *Cancer Chemotherapy and Pharmacology* , **2010**, 65, 863-9 | 3.5 | |
| 4 | Precision Medicine in Metastatic Colorectal Cancer Binding and Hitting the Right Targets. *Oncology & Hematology Review*, **2020**, 16, 36 | 0.1 | |
| 3 | Systemic Treatment for Metastatic or Recurrent Disease **2020**, 275-287 | | |
| 2 | Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. *Oncologist*, **2021**, 26, 610-618 | 5.7 | |
| 1 | Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data-Reply. *JAMA Oncology*, **2021**, 7, 941 | 13.4 | |